Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria

BACKGROUND: Remission is the established goal in rheumatoid arthritis (RA) treatment. Although originally defined by a disease activity score in 28 joints (DAS28) <2.6, more stringent criteria may imply the absence of disease activity. The 2011 ACR/EULAR remission criteria provide the newest and...

Descripción completa

Detalles Bibliográficos
Autores principales: Iking-Konert, Christof, Aringer, Martin, Wollenhaupt, Jürgen, Mosch, Thomas, Tuerk, Stefan, Feist, Eugen, Burmester, Gerd R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2011
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184242/
https://www.ncbi.nlm.nih.gov/pubmed/21875873
http://dx.doi.org/10.1136/ard.2011.152678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184242/
https://www.ncbi.nlm.nih.gov/pubmed/21875873
http://dx.doi.org/10.1136/ard.2011.152678

Ejemplares similares